14 registrations that name thiamine as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 14 registrations
Status
Phase
5US sites across 4 states
1
2 to 4
5 to 19
20 or more
All 14 registrations
RecruitingNCT06322212
Type 2 Diabetes and Blood Brain Barrier Improvement
Early phase 1
University of California, Los Angeles
About 52 people
Started Aug 1, 2024
In plain words An early phase 1 study of thiamine in people 40 to 65, run by University of California, Los Angeles. It plans to enroll about 52 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 40 to 65. Conditions: Type2diabetes.
Diagnosed T2DM
Outpatient status
Able to lay flat for imaging
The exclusion criteria are on the listing.
What it tests, as registered
Thiamine; Placebo
Registered summary
The majority of T2DM adults show thiamine (vitamin B1) deficiency which may contribute to impaired function. This study will examine patients with T2DM through brain MRI scans, cognition assessments, blood tests, and questionnaires. Our goal is to see if a thiamine treatment (taking vitamin B1 capsules) can improve function. Patients will be asked to come to UCLA two times three months apart and each visit will last about 2.5-3 hours.
Where, as registered
1 US site in 1 state.
RecruitingNCT06326996
Thiamine Intervention and Coronary Artery Bypass Grafting
Early phase 1
University of California, Los Angeles
About 52 people
Started Oct 10, 2024
In plain words An early phase 1 study of thiamine in people 60 to 80, run by University of California, Los Angeles. It plans to enroll about 52 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 60 to 80. Conditions: Coronary Heart Disease; Coronary Artery Bypass Grafting.
Patients with Coronary Heart Disease (CHD) scheduled for Bypass Grafting (CABG)
Thiamine deficiency before CABG
European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) >1.5%
Off-pump surgery
The exclusion criteria are on the listing.
What it tests, as registered
Thiamine; Placebo
Registered summary
The purpose of this study is to gain a better understanding of the association between brain changes and cognitive deficits in coronary heart disease (CHD) patients undergoing coronary artery bypass grafting (CABG) and whether a low-cost thiamine intervention can be used to reduce post-CABG cognitive issues in CHD subjects.
Where, as registered
1 US site in 1 state.
RecruitingNCT07046429
Affect of Melatonin on Sleep and Cognition in Cirrhosis
No phase
Weill Medical College of Cornell University
About 18 people
Started Aug 5, 2025
In plain words A study of thiamine in people 18 and older, run by Weill Medical College of Cornell University. It plans to enroll about 18 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Hepatic Encephalopathy; Covert Hepatic Encephalopathy; Cirrhosis; Sleep Disturbances and Insomnia.
Cirrhosis with clinically significant portal hypertension or decompensation defined by Baveno VII criteria \[de Franchis R et al 2022\]
Adults over age 18
CHE (defined by PHES≤ -4) or previously diagnosed HE
Disturbed sleep, with Pittsburgh Sleep Quality Index (PSQI) ≥5
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Melatonin tablet 3 mg once daily; Thiamine
Registered summary
The goal of this clinical trial is to learn the affect of melatonin on sleep, cognitive function, and quality of life (QoL) in patients with cirrhosis and a complication called hepatic encephalopathy (HE). The main questions this study aims to answer are: * Does taking melatonin increase REM sleep, an important part of healthy sleep that is reduced in cirrhosis? * Does taking melatonin improve cognitive function and reported QoL? This is a pilot study, where participants will: * take one month of melatonin, followed by one month of thiamine, which is another supplement but is not suspected to… The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT05873881
COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease
Phase 3
Hamilton Health Sciences Corporation
About 2,500 people
Started Jan 29, 2024
In plain words A Phase 3 study of thiamine in people 45 and older, run by Hamilton Health Sciences Corporation. It plans to enroll about 2,500 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 45 and older. Conditions: Heart Failure.
Age >/= 45 years
Documented ischemic HF as the etiology of HF, which includes:
a prior history of CAD (defined as a history of myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, or non-invasive or invasive cardiac testing consistent with a diagnosis of CAD), and
determination of CAD to be the cause primary cause of HF based on local investigator assessment
4 more inclusion criteria and the exclusion criteria are on the listing.
The goal of this 2x2 factorial clinical trial is to test the efficacy of i) colchicine, and ii) thiamine in heart failure (HF) secondary to ischemic heart disease. The main questions it aims to answer are: * Does colchicine reduce the risk of cardiovascular (CV) death, a HF event, or an ischemic CV event * Does thiamine reduce the risk of cardiovascular (CV) death, or a HF event Participants will undergo the following procedures: * Run-in: All participants will receive colchicine 0.5 mg daily to assess drug tolerance over a 3-4 week period. The full summary is on the listing.
Where, as registered
No US site; Canada (1).
RecruitingNCT07405814
Clinical Trial On The Effect Of Artisterol On Risk Factors In Individuals With Suboptimal Cholesterol Levels
No phase
Zentiva, k.s.
About 106 people
Started Apr 24, 2026
In plain words A study of thiamine in people 18 to 70, run by Zentiva, k.s.. It plans to enroll about 106 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: Hyperlipoproteinemia.
Female or male, 18-70 years old.
Subjects with mild hypercholesterolemia previously untreated (LDL-C levels between 115 and 160 mg/dL.
Written informed consent has been obtained during screening visit prior to any study specific procedure.
Subject must understand the informed consent form and other study documents and are willing and able to comply with scheduled visits and requirements of the study protocol, including study specific Dietary Recommendations .
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
investigational product containing phytosterol, artichoke extract and thiamin; Placebo
Registered summary
The goal of this clinical trial is to learn if Artisterol works to lower LDL cholesterol and other metabolic and vascular risk factors in adults. The main questions it aims to answer are: • Does Artisterol lower low-density lipoprotein cholesterol (LDL-C) levels in participants and by how much? Researchers will compare Artisterol to a placebo (a look-alike substance that contains no drug) to see if Artisterol works to lower LDL cholesterol. The full summary is on the listing.
Where, as registered
No US site; Poland (1).
RecruitingNCT07877948
Comparative Study of Combination Treatment of Bionerv E+ Versus Vitamin B Complex in Treatment of Diabetic Polyneuropathy in Type 2 Diabetic Patients and Its Effect on Wound Healing
No phase
BREGO Life Sciences
About 100 people
Started Jul 22, 2025
In plain words A study of thiamine in people 18 and older, run by BREGO Life Sciences. It plans to enroll about 100 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Diabetic Foot Ulcer (DFU); Diabetic Symmetrical Polyneuropathy.
Aged 18 years and above
Diagnosed with Type 2 Diabetes Mellitus
HbA1C of <8%
Symptoms of DSPN attributed by diabetes mellitus using Toronto Clinical Neuropathy Scoring (TCNS)
12 more inclusion criteria and the exclusion criteria are on the listing.
Diabetic symmetrical polyneuropathy (DSPN) is a common complication of diabetes that affects the nerves, especially in the legs and feet. It can cause pain, numbness, tingling, weakness, and loss of sensation. These problems can affect daily activities and quality of life. Loss of sensation can also increase the risk of foot wounds and problems with wound healing. This study is comparing two treatments in people with type 2 diabetes and DSPN. The full summary is on the listing.
Where, as registered
No US site; Malaysia (1).
RecruitingNCT07312123
A Study to See Whether Taking a Mix of Vitamins Can Help Adults Recover Better After Surgery for Carpal Tunnel Syndrome
No phase
Hospital Universiti Sains Malaysia
About 84 people
Started Dec 8, 2025
In plain words A study of thiamine in people 18 and older, run by Hospital Universiti Sains Malaysia. It plans to enroll about 84 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Carpal Tunnel Syndrome.
Age more than 18 years old
Subjects with symptoms and physical examination of CTS
Patients with CTS going for CT release
The exclusion criteria are on the listing.
What it tests, as registered
Alpha-Lipoic Acid, Vitamin E, and Vitamin B Complex; Combination Vitamin B1,B6,B12
Registered summary
Carpal Tunnel Syndrome (CTS) is a common condition that causes numbness, tingling, pain, and weakness in the hand due to compression of the median nerve at the wrist. It can affect daily activities, work performance, and quality of life. While surgery is effective in severe cases, many patients with mild to moderate CTS are initially treated with non-surgical options such as splinting and medications. However, the effectiveness of oral supplements for CTS remains uncertain. The full summary is on the listing.
Where, as registered
No US site; Malaysia (1).
RecruitingNCT07665658
Effectiveness of Neuroplasticity-Targeted Supplements on Neuroinflammatory Markers, ADHD Symptom Severity, and Clinical Scores in Children
No phase
Khyber Medical University Peshawar
About 68 people
Started Mar 1, 2026
In plain words A study of thiamine in people 6 to 12, run by Khyber Medical University Peshawar. It plans to enroll about 68 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 6 to 12. Conditions: Attention Deficit Hyperactivity Disorder.
DSM-5 confirmed ADHD diagnosis
Age 6-12 years
Medication-free or on stable stimulant medication (≥1 month)
This randomized controlled trial will evaluate the effectiveness of neuroplasticity-targeted supplements on neuroinflammatory markers and ADHD symptoms in children aged 6 to 12 years diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). Participants will be randomly assigned to one of four groups: gut-targeted supplements (prebiotics and probiotics), brain-targeted supplements (omega-3 fatty acids and vitamin B1), combined supplementation, or placebo. The intervention period will last 12 weeks. The full summary is on the listing.
Where, as registered
No US site; Pakistan (1).
RecruitingNCT07708233
Benfotiamine Versus Vitamin B1-6-12 for Diabetic Peripheral Neuropathy
Phase 4
Thammasat University
About 66 people
Started Jul 14, 2026
In plain words A Phase 4 study of thiamine in people 18 and older, run by Thammasat University. It plans to enroll about 66 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Diabetic Peripheral Neuropathy (DPN).
Age ≥18 years.
Diagnosis of diabetic peripheral neuropathy confirmed by a physician based on the following ICD-10 codes: E11.42: Type 2 diabetes mellitus with diabetic polyneuropathy; or E11: Type 2 diabetes mellitus, combined with either:
Presence of sensory neuropathy symptoms assessed using the Neuropathy Total Symptom Score-6 (NTSS-6), with: Total NTSS-6 score ≥1; and Numbness symptom score (NTSS-6 item 6) ≥1.
No evidence of vitamin B12 deficiency, defined as a serum vitamin B12 level ≥200 pg/mL (148 pmol/L).
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Benfotiamine; Vitamin B1-6-12
Registered summary
The purpose of this clinical trial is to compare the efficacy of benfotiamine with vitamin B1-6-12 in reducing sensory neuropathy symptoms, numbness and pain in patients with diabetic peripheral neuropathy. The main questions this study aims to answer are: * Does benfotiamine reduce overall sensory neuropathy symptoms more effectively than vitamin B1-6-12? * Does benfotiamine reduce numbness more effectively than vitamin B1-6-12? * Does benfotiamine reduce pain more effectively than vitamin B1-6-12? Researchers will compare benfotiamine with vitamin B1-6-12 in a double-blind study. The full summary is on the listing.
Where, as registered
No US site; Thailand (1).
RecruitingNCT06959251
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia
No phase
Instituto Nacional de Enfermedades Respiratorias
About 60 people
Started Oct 2, 2025
In plain words A study of thiamine in people 5 and older, run by Instituto Nacional de Enfermedades Respiratorias. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 5 and older. Conditions: Primary Ciliary Dyskinesia.
Any sex.
Age of 5 years or more.
Diagnosis of primary ciliary dyskinesia (PCD) established according to international recommendations (Shapiro et al. Am J Respir Crit Care Med 2018;197(12):e24-e39, and Shapiro et al. Ped Pulmonol 2016;51:115-132).
Without respiratory exacerbations of PCD in the previous 30 days.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Glycine; Magnesium+thiamine; Placebo
Registered summary
* Patients with primary ciliary dyskinesia (PCD) have trouble with clearing their bronchi from mucus, which in the long-term may produce severe damage to the lungs. Currently, there is no specific treatment for PCD beyond supportive measures such as airway hydration and postural drainage. * Glycine is an amino acid with anti-inflammatory properties that proved to be beneficial in another disease with problematic airway clearance, cystic fibrosis. * Magnesium participates in many crucial chemical reactions, including some that might favor fluidification and mobilization of mucus. The full summary is on the listing.
Where, as registered
No US site; Mexico (1).
Not yet recruitingNCT07868679
THiamine for Recovery In Vulnerable Early-life Infections
Phase 2
Milton S. Hershey Medical Center
About 240 people
Starts Dec 1, 2026 (estimated)
In plain words A Phase 2 study of thiamine in people up to 12 months, run by Milton S. Hershey Medical Center. It plans to enroll about 240 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people up to 12 months. Conditions: Meningitis; Bacteremia.
≤12 months old
Clinical concern for bacteremia or meningitis (fever or hypothermia and lethargy; fever or hypothermia and poor feeding; fever or hypothermia and seizure, bulging fontanelle or nuchal rigidity)
Legal guardian has provided informed consent
No known neurologic or developmental comorbidity (e.g. trisomy 21, congenital structural brain abnormality)
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
thiamine hydrochloride 100 mg; Placebo
Registered summary
To determine if the addition of thiamine to standard-of-care treatment will improve neurodevelopmental outcomes for infants with meningitis or bacteremia
Where, as registered
2 US sites in 2 states.
Not yet recruitingNCT07844720
Study on Thiamine Supplementation to REduce braiN Injury Associated With Chronic Alcohol Use in Outpatients With Alcohol Use Disorder
Phase 2
Institut National de la Santé Et de la Recherche Médicale, France
About 60 people
Starts Oct 23, 2026 (estimated)
In plain words A Phase 2 study of thiamine in people 18 to 65, run by Institut National de la Santé Et de la Recherche Médicale, France. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Alcohol Use Disorder.
Patient with moderate to severe alcohol use disorder
Reported daily consumption of at least 40g of alcohol
Patients aged 18 to 65
Urine pregnancy test performed prior to inclusion for women of childbearing age
15 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Thiamine
Registered summary
Chronic alcohol use and alcohol use disorder (AUD) affect 10% of the population in France. They are associated with brain damage and cognitive impairment. These complications have a significant impact on patients' agency, autonomy, and ability to participate in their own care. The investigators need to improve our knowledge of medical treatments that can reduce these risks and harms, beyond providing support to quit drinking or reduce consumption. Nutritional and vitamin deficiencies, particularly thiamine deficiency, are involved in the onset of these complications. The full summary is on the listing.
Where, as registered
No US site; France (1).
Not yet recruitingNCT07793071
Oral Thiamine (Vitamin B1) for Depression in Children and Adolescents
Phase 2
Massachusetts General Hospital
About 40 people
Starts Oct 1, 2026 (estimated)
In plain words A Phase 2 study of thiamine in people 8 to 17, run by Massachusetts General Hospital. It plans to enroll about 40 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 8 to 17. Conditions: Major Depressive Disorder (MDD); Thiamine; Vitamin B1; Thiamine Diphosphate (TDP); Pediatrics.
Male or female participants aged 8 to 17.5 years (inclusive) at the time of enrollment
Diagnosis of major depressive disorder (MDD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
Evidence of clinically significant symptoms of depression as indicated by a T score> 60 on the Children's Depression Inventory 2 (CDI-2) parent form at prescreening
Evidence of clinically significant symptoms of depression in the mild to moderate range as indicated by a score between 40 and 70 on the Children's Depression Rating Scale--Revised (CDRS-R) at screening
6 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
thiamine hydrochloride 100 mg
Registered summary
The goal of this study is to examine the effectiveness of thiamine in reducing depressive symptoms in children and adolescents. The investigators hypothesize that thiamine administration will alleviate depressive symptoms in children and adolescents and will have a favorable safety profile. Participants will complete a baseline virtual visit with a study clinician and parent/guardian questionnaires to assess depression symptoms, medical history, current medications, and study eligibility. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07475299
Synbiotic Supplement With Botanical Extracts for Gut Microbiota Balance in Irritable Bowel Syndrome
No phase
Iuliu Hatieganu University of Medicine and Pharmacy
About 8 people
Starts Apr 2026 (estimated)
In plain words A study of thiamine in people 18 to 70, run by Iuliu Hatieganu University of Medicine and Pharmacy. It plans to enroll about 8 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: Irritable Bowel Syndrome (IBS).
Adults aged ≥18 years
Clinically confirmed diagnosis of Irritable Bowel Syndrome documented in the medical record
Presence of recurrent gastrointestinal symptoms such as bloating, abdominal discomfort, gas, or bowel habit disturbances (constipation, diarrhea, or mixed pattern) considered clinically relevant by the participant
Ability to understand the study procedures and provide written informed consent
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Synbiotic supplement containing probiotic strains, botanical extracts, magnesium, vitamin B1, and L-theanine designed to support gut microbiota balance.
Registered summary
The goal of this clinical trial is to evaluate whether a synbiotic dietary supplement containing botanical extracts and multiple probiotic strains can improve gastrointestinal symptoms and modulate gut microbiota composition in adults diagnosed with Irritable Bowel Syndrome (IBS). The full summary is on the listing.